RSH in the USA, page-3

Thanks @Diamo. I’m not a Switzer fan but that was a good interview. Most of the first half everyone will know but it gave some great highlights on US performance since launching in December:

- US$200,000 in sales of product & services already
- 60 qualified leads
- “quite remarkable response” to Wheezo especially given RPM is new to the pulmonology space
- MM off to the US today/tomorrow to ‘press the flesh’
- very honest comments about “painful lessons” learned in Australia which frankly is what you want to see/hear

I’ll take all example numbers provided (i.e. 1% market penetration equating to ~$70M annual revenue) with a big pinch of salt given past experiences but it’s looking quite promising to me if they keep executing this.

Cheers